1 INTRODUCTION
1.1 MARKET SEGMENTATION

2 RESEARCH METHODOLOGY
2.1 ECOSYSTEM OF GLOBAL HUMAN MICROBIOME MARKET
2.2 TOP-DOWN APPROACH
2.3 BOTTOM-UP APPROACH
2.4 ASSUMPTIONS

3 EXECUTIVE SUMMARY
3.1 GLOBAL HUMAN MICROBIOME MARKET SNAPSHOT

4 MARKET OVERVIEW
4.1 INTRODUCTION
4.2 KEY TRENDS ANALYSIS
4.3 PORTERS FIVE FORCE ANALYSIS
4.4 VALUE CHAIN ANALYSIS

5 GLOBAL HUMAN MICROBIOME MARKET, BY DISEASES
5.1 OVERVIEW
5.2 CANCER
5.3 DIABETES
5.4 OBESITY
5.5 ACUTE DIARRHEA/METABOLIC DISORDERS
5.6 AUTO IMMUNE DISORDERS
5.7 MENTAL DISORDERS
5.8 ATOPIC DERMATITIS
5.9 OTHER DISEASES

6 GLOBAL HUMAN MICROBIOME MARKET, BY TECHNOLOGY
6.1 OVERVIEW
6.2 CELL CULTURE TECHNOLOGY
6.3 OMICS TECHNOLOGY
6.4 HIGH-THROUGHPUT TECHNOLOGY
6.5 COMPUTATIONAL TOOLS TECHNOLOGY

7 GLOBAL HUMAN MICROBIOME MARKET, BY PRODUCT
7.1 OVERVIEW
7.2 CONSUMABLES
7.3 INSTRUMENTS

8 GLOBAL HUMAN MICROBIOME MARKET, BY END-USE
8.1 OVERVIEW
8.2 PREBIOTICS
8.3 PROBIOTICS
8.4 OTHER PROBIOTIC SUPPLEMENTS
8.5 FOODS
8.6 MEDICAL FOODS
8.7 DRUGS
8.8 DIAGNOSTIC DEVICES

9 GLOBAL HUMAN MICROBIOME MARKET, BY GEOGRAPHY
9.1 NORTH AMERICA
9.1.1 MARKET DYNAMICS
9.1.2 U.S.
9.1.3 CANADA
9.1.4 MEXICO
9.2 EUROPE
9.2.1 MARKET DYNAMICS
9.2.2 U.K.
9.2.3 ITALY
9.2.4 FRANCE
9.2.5 GERMANY
9.2.6 RUSSIA
9.2.7 SPAIN
9.2.8 REST OF EUROPE
9.3 ASIA PACIFIC
9.3.1 MARKET DYNAMICS
9.3.2 INDIA
9.3.3 CHINA
9.3.4 JAPAN
9.3.5 AUSTRALIA
9.3.6 REST OF ASIA PACIFIC
9.4 MIDDLE EAST AND AFRICA
9.4.1 MARKET DYNAMICS
9.4.2 GCC
9.4.3 SOUTH AFRICA
9.4.4 REST OF MIDDLE EAST AND AFRICA
9.5 LATIN AMERICA
9.5.1 MARKET DYNAMICS
9.5.2 BRAZIL
9.5.3 REST OF LATIN AMERICA

10 COMPETATIVE LANDSCAPE
10.1 OVERVIEW
10.2 MARKET SHARE ANALYSIS
10.3 PATENT ANALYSIS

11 GLOBAL HUMAN MICROBIOME MARKET, BY COMPANY
11.1 INTRODUCTION
11.2 ACTOGENIX
11.2.1 BUSINESS OVERVIEW
11.2.2 PRODUCTS & SERVICES
11.2.3 KEY STRATEGY
11.2.4 RECENT DEVELOPMENTS
11.2.5 SWOT ANALYSIS
11.3 AVIDBIOTICS
11.3.1 BUSINESS OVERVIEW
11.3.2 PRODUCTS & SERVICES
11.3.3 KEY STRATEGY
11.3.4 RECENT DEVELOPMENTS
11.3.5 SWOT ANALYSIS
11.4 DUPONT
11.4.1 BUSINESS OVERVIEW
11.4.2 PRODUCTS & SERVICES
11.4.3 KEY STRATEGY
11.4.4 RECENT DEVELOPMENTS
11.4.5 SWOT ANALYSIS
11.5 ENTEROME BIOSCIENCE
11.5.1 BUSINESS OVERVIEW
11.5.2 PRODUCTS & SERVICES
11.5.3 KEY STRATEGY
11.5.4 RECENT DEVELOPMENTS
11.5.5 SWOT ANALYSIS
11.6 METABIOMICS CORPORATION
11.6.1 BUSINESS OVERVIEW
11.6.2 PRODUCTS & SERVICES
11.6.3 KEY STRATEGY
11.6.4 RECENT DEVELOPMENTS
11.6.5 SWOT ANALYSIS
11.7 MERCK & CO.
11.7.1 BUSINESS OVERVIEW
11.7.2 PRODUCTS & SERVICES
11.7.3 KEY STRATEGY
11.7.4 RECENT DEVELOPMENTS
11.7.5 SWOT ANALYSIS
11.8 MICROBIOME THERAPEUTICS LLC
11.8.1 BUSINESS OVERVIEW
11.8.2 PRODUCTS & SERVICES
11.8.3 KEY STRATEGY
11.8.4 RECENT DEVELOPMENTS
11.8.5 SWOT ANALYSIS
11.9 OPTIBIOTIX HEALTH PLC
11.9.1 BUSINESS OVERVIEW
11.9.2 PRODUCTS & SERVICES
11.9.3 KEY STRATEGY
11.9.4 RECENT DEVELOPMENTS
11.9.5 SWOT ANALYSIS
11.10 OSEL
11.10.1 BUSINESS OVERVIEW
11.10.2 PRODUCTS & SERVICES
11.10.3 KEY STRATEGY
11.10.4 RECENT DEVELOPMENTS
11.10.5 SWOT ANALYSIS
11.11 RITTER PHARMACEUTICALS, INC.
11.11.1 BUSINESS OVERVIEW
11.11.2 PRODUCTS & SERVICES
11.11.3 KEY STRATEGY
11.11.4 RECENT DEVELOPMENTS
11.11.5 SWOT ANALYSIS
11.12 SERES THERAPEUTICS
11.12.1 BUSINESS OVERVIEW
11.12.2 PRODUCTS & SERVICES
11.12.3 KEY STRATEGY
11.12.4 RECENT DEVELOPMENTS
11.12.5 SWOT ANALYSIS
11.13 SECOND GENOME, INC.
11.13.1 BUSINESS OVERVIEW
11.13.2 PRODUCTS & SERVICES
11.13.3 KEY STRATEGY
11.13.4 RECENT DEVELOPMENTS
11.13.5 SWOT ANALYSIS
11.14 VEDANTA BIOSCIENCES
11.14.1 BUSINESS OVERVIEW
11.14.2 PRODUCTS & SERVICES
11.14.3 KEY STRATEGY
11.14.4 RECENT DEVELOPMENTS
11.14.5 SWOT ANALYSIS
11.15 VITHERA PHARMACEUTICALS
11.15.1 BUSINESS OVERVIEW
11.15.2 PRODUCTS & SERVICES
11.15.3 KEY STRATEGY
11.15.4 RECENT DEVELOPMENTS
11.15.5 SWOT ANALYSIS
11.16 YAKULT HONSHA CO., LTD
11.16.1 BUSINESS OVERVIEW
11.16.2 PRODUCTS & SERVICES
11.16.3 KEY STRATEGY
11.16.4 RECENT DEVELOPMENTS
11.16.5 SWOT ANALYSIS